NasdaqCM:CORTPharmaceuticals
Why Corcept Therapeutics (CORT) Is Up 6.1% After Resubmitting Its Cushing’s Drug NDA to FDA
Corcept Therapeutics has resubmitted its New Drug Application to the FDA for relacorilant in Cushing’s syndrome, incorporating additional analyses of existing clinical data as requested by regulators, with the company indicating it expects a six‑month review period.
This resubmission leans heavily on positive results from the pivotal GRACE trial, the placebo‑controlled Phase III GRADIENT trial, and long‑term extension data, highlighting relacorilant’s central role in Corcept’s...